CIK 0001001233
- Non-accelerated filer
- Smaller reporting company
SANGAMO THERAPEUTICS, INC
Sign in to watch- Ticker
- SGMOQ
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680359556
- Phone
- +1 510-970-6000
- Business address
- 501 CANAL BLVD., RICHMOND, CA, 94084
- Former names
- SANGAMO BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-04-25 | Fontenot Jason D. SVP, Chief Scientific Officer | Shares withheld for taxes | −826 | $4.83 | $4K | 103,167 |
| 2022-04-25 | Duraibabu Prathyusha Vice President, Finance | Shares withheld for taxes | −662 | $4.83 | $3K | 86,772 |
| 2022-04-24 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Shares withheld for taxes | −3,976 | $4.70 | $19K | 90,849 |
| 2022-03-25 | Duraibabu Prathyusha Vice President, Finance | Shares withheld for taxes | −345 | $5.75 | $2K | 87,434 |
| 2022-02-25 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Shares withheld for taxes | −1,566 | $5.90 | $9K | 53,825 |
| 2022-02-25 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Grant or award | +41,000 | 94,825 | ||
| 2022-02-25 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Grant or award · Stock Option (Right to Buy) | +110,700 | 110,700 | ||
| 2022-02-25 | Schott Robert J. SVP, Head of Development | Grant or award | +41,000 | 75,537 | ||
| 2022-02-25 | Schott Robert J. SVP, Head of Development | Grant or award · Stock Option (Right to Buy) | +110,700 | 110,700 | ||
| 2022-02-25 | Ramelmeier Rolf Andrew EVP, Technical Operations | Shares withheld for taxes | −12,388 | $5.90 | $73K | 88,429 |
| 2022-02-25 | Ramelmeier Rolf Andrew EVP, Technical Operations | Grant or award | +54,000 | 142,429 | ||
| 2022-02-25 | Ramelmeier Rolf Andrew EVP, Technical Operations | Grant or award · Stock Option (Right to Buy) | +145,800 | 145,800 | ||
| 2022-02-25 | Fontenot Jason D. SVP, Chief Scientific Officer | Shares withheld for taxes | −6,248 | $5.90 | $37K | 58,893 |
| 2022-02-25 | Fontenot Jason D. SVP, Chief Scientific Officer | Grant or award | +45,100 | 103,993 | ||
| 2022-02-25 | Fontenot Jason D. SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +121,770 | 121,770 | ||
| 2022-02-25 | Duraibabu Prathyusha Vice President, Finance | Shares withheld for taxes | −3,474 | $5.90 | $20K | 46,779 |
| 2022-02-25 | Duraibabu Prathyusha Vice President, Finance | Grant or award | +41,000 | 87,779 | ||
| 2022-02-25 | Duraibabu Prathyusha Vice President, Finance | Grant or award · Stock Option (Right to Buy) | +110,700 | 110,700 | ||
| 2022-02-25 | McClung David Mark EVP, Chief Operating Officer | Shares withheld for taxes | −4,610 | $5.90 | $27K | 125,584 |
| 2022-02-25 | McClung David Mark EVP, Chief Operating Officer | Grant or award | +59,400 | 184,984 |
Page 13 of 17 · 338 trades